Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBF-1129 in Advanced NSCLC
NCT03274479Phase 1Active, not recruiting
- Sponsor
- Palobiofarma
- Start
- Oct 2018
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PBF-1129 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Palobiofarma. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Oct 2018; status: active, not recruiting.
02
Drugs
PBF-1129
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03274479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274479.